When Kolkata flooded, Suraksha’s scanners practically needed lifejackets. Patients stayed home, doctors stayed dry, and diagnostic centers turned into waterproof warehouses. Yet amid this soggy quarter, management decided to dream bigger—adding new centers, launching a genomic arm, and promising 15% growth like the rain was just a minor drizzle. It’s the classic Indian healthcare story: power cuts, puddles, and profitability. And just when you think it’s over, the CFO brings up GST, rent, and professional fees in the same breath. Grab your umbrella—this call gets interesting. ☔
EPS ₹3.53 (vs ₹3.43): Flat, but at least not underwater.
Centers 63 (↑3 QoQ): Growth is spreading faster than dengue season.
3. Management’s Key Commentary
“We launched Suraksha Genomics, a landmark move into molecular testing.” (Translation: Everyone’s doing DNA tests now; we didn’t want to be left behind.) 🧬
“Heavy rains and early festivities impacted our operations.” (Translation: Kolkata turned into Venice, and Puja got promoted to a business risk.)
“33% of our centers are yet to mature.” (Translation: Two-thirds make money, one-third burns it—balance achieved.)
“We’re on track to 15% growth and 33–34% EBITDA margin.” (Translation: Optimism remains immune to waterlogging.)
“Genomics and Fetomat Wellness will be future growth drivers.” (Translation: If the tests don’t make money, the buzzwords surely will.) 😏
“Mature centers deliver 37–38% margins; new ones dilute overall numbers.” (Translation: Newborn centers cry a lot before walking.)
“Corporate costs will spread over more centers.” (Translation: Same air conditioning, more people paying for it.)
